机构：[1]LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.[2]Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[3]UCD School of Medicine, College of Health and Agricultural Science and UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, UCD, Dublin 4, Ireland.[4]State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China.
The funding was provided by National Institutes of Health Grants RO1CA050947,
RO1CA207237 and P50CA100707; KCA is an American Cancer Society Clinical
Research. Professor Dr Li Zhang was supported in part by the Research Development
Fund for Hematological Neoplasm from Chinese Anti-Cancer Association
(312160342), and the Young Scholars Grant from the National Natural Science
Foundation of China (81302148)
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2017]版：
大类|2 区医学
小类|2 区肿瘤学
最新[2023]版：
大类|1 区医学
小类|1 区血液学1 区肿瘤学
第一作者：
第一作者机构：[1]LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.[2]Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
推荐引用方式(GB/T 7714)：
Zhang L,Tai Y-T,Ho M,et al.Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu.[J].Blood cancer journal.2017,7(3):e547.doi:10.1038/bcj.2017.24.
APA：
Zhang L,Tai Y-T,Ho M,Xing L,Chauhan D...&Anderson K C.(2017).Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu..Blood cancer journal,7,(3)
MLA：
Zhang L,et al."Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu.".Blood cancer journal 7..3(2017):e547
医学